Anti-viral prophylaxis for prevention of cytomegalovirus (CMV) reactivation in immunocompetent patients in critical care.

Trial Profile

Anti-viral prophylaxis for prevention of cytomegalovirus (CMV) reactivation in immunocompetent patients in critical care.

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Apr 2017

At a glance

  • Drugs Aciclovir (Primary) ; Ganciclovir (Primary) ; Valaciclovir (Primary) ; Valganciclovir (Primary)
  • Indications Cytomegalic inclusion disorders
  • Focus Proof of concept; Therapeutic Use
  • Acronyms CCCC
  • Most Recent Events

    • 24 Apr 2017 Results published in the JAMA Internal Medicine
    • 11 Jan 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 31 Dec 2011 Additional lead trial centre (National Institute for Health Research) and investigators identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top